Recent Company News

• 03:04 AM ET Sep 19, 2025
  

  Astellas Pharma receives conditional approval for IZERVAY for treatment of suppression of geographic atrophy growth (¥1657.5000, 0)

• 06:23 PM ET Sep 18, 2025
  

  Astellas Pharma upgraded to buy from neutral at BofA (¥1650.0000, 0)

• 08:58 PM ET Sep 10, 2025
  

  NICE recommends Pfizer's Padcev with Merck's Keytruda for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable

• 07:03 AM ET Sep 02, 2025
  

  FibroGen completes sale of FibroGen China to AstraZeneca (AZN.LN) for ~$220M ($11.83, 0.00)

• 05:15 AM ET Sep 02, 2025
  

  Astellas Pharma downgraded to market perform from outperform at Bernstein (¥1659.0000, 0)

• 05:49 AM ET Aug 12, 2025
  

  Pfizer, Astellas Pharma's Phase 3 EV-303 clinical trial meet primary and secondary endpoints

• 10:41 PM ET Jul 30, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:14 PM ET Jul 30, 2025
  

  Japan post-close earnings highlights:

• 02:38 AM ET Jul 30, 2025
  

  Astellas Pharma reports Q1 core profit ¥104.72B vs year-ago ¥67.15B and FactSet ¥49.71B (¥1488.0000, 0)

• 10:57 AM ET Jul 29, 2025
  

  Glass Lewis, ISS vs Texas; new corporate data collection and reporting tools among ESG products & ratings highlights Jun-Jul